
|Articles|November 6, 2006
Accredo to distribute Elaprase
Advertisement
Accredo Health Group has been chosen as a specialty pharmacy provider for the new replacement enzyme idursulfase (Elaprase, Shire Genetic Therapies), used to treat Hunter syndrome, a rare, but life-threatening lysosomal storage disorder. Accredo will provide pharmacy management and prescription fulfillment services through its network of 39 pharmacies. Caremark Specialty Pharmacy will be the other provider to distribute the therapy.
To see more Hot off the Press news articles,
To go to the Drug Topics homepage,
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
ICER Report Finds GLP-1s Are Cost-Effective But Warns of Budget Strain
2
New Study Finds Compounded GLP-1s Remain Robust Despite End of Shortages
3
Postpartum Mothers Favor Bedtime Stopping Rule Over Stricter Chrononutrition Approaches
4
What’s Next for Pneumococcal Vaccination? An Expert Weighs In
5






























